An experienced entrepreneur and gene therapy pioneer, Boro has been in the gene therapy field since the late 1980s. He currently serves as the Executive Director and Co-Founder of Caring Cross and the Chief Executive Officer at Vector BioMed. A career dedicated to challenging what’s possible in the scientific community, he previously founded four organizations to bring Lentiviral vector (LV)-based solutions to the forefront of state-of-the-art therapeutic development.

Dr. Dropulić previously founded ViRxSys and led the team to successfully complete the first clinical trial in humans using LV. Next, he founded Lentigen, which first developed the LV used to produce Kymriah®, the first-FDA-approved gene therapy product. Lentigen was later acquired by Miltenyi Biotec in 2014. Now, Boro is focused on democratizing LV-based advanced therapies for tangible patient access across the globe.

Boro holds a PhD from the University of Western Australia and an MBA from the Johns Hopkins University.